

Supplementary Materials for
Consolidated Financial Results
for the 3rd Quarter of Fiscal Year 2009. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Extraordinary Gains and Losses, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Amounts by quarter for the fiscal year ended December 2008 and indicators are presented as comparisons with the same period of the previous fiscal year for reference purposes.
4. Exchange rates used for each period are as follows.

(Yen)

Fx rates	FY2006	FY2007	FY2008				FY2009				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2009
	(Full-year)	(Full-year)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(Full-year)
	end-of-year closing	average	average	average	average	average	average	average	average	average	forecast
CHF	97.44	98.13	98.58	99.95	100.08	95.54	81.55	84.52	85.68	-	85.00
EUR	156.57	161.17	157.85	160.54	160.93	151.38	122.06	127.19	129.32	-	125.00
USD	119.12	117.80	105.43	104.98	105.85	103.44	93.51	95.46	94.87	-	90.00
GBP	233.70	235.66	208.56	207.31	206.00	189.85	134.34	142.14	145.77	-	135.00

Financial Highlights (YTD)

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009								Forecasts			
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	1-9	Change (%)	1-12	Change (%)	FY2009		Change (%)	Change (%)	
	Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD	YTD		YTD		Half-year(Actual)	Full-year			
Revenues	326.1	344.8	66.2	145.9	229.7	326.9	94.7	+43.1	191.7	+31.4	309.7	+34.8	-	-	191.7	+31.4	420.0	+28.5
Sales	326.1	332.9	65.9	144.9	224.9	321.8	92.9	+41.0	185.9	+28.3	303.4	+34.9	-	-	185.9	+28.3	410.0	+27.4
excl. Tamiflu	288.2	294.3	64.4	143.3	223.2	313.4	72.5	+12.6	160.6	+12.1	247.6	+10.9	-	-	160.6	+12.1	345.2	+10.1
Tamiflu	38.0	38.7	1.6	1.6	1.7	8.4	20.4	+1,175.0	25.4	+1,487.5	55.8	+3,182.4	-	-	25.4	+1,487.5	64.9	+672.6
Ordinary sales	13.6	10.2	1.3	1.4	1.5	7.1	6.0	+361.5	11.0	+685.7	18.5	+1,133.3	-	-	11.0	+685.7	-	-
Govt. stockpile etc.	24.4	28.5	0.2	0.2	0.2	1.3	14.4	+7,100.0	14.4	+7,100.0	37.3	+18,550.0	-	-	14.4	+7,100.0	-	-
Other operating revenues *	-	11.9	0.2	1.0	4.8	5.1	1.8	+800.0	5.7	+470.0	6.3	+31.3	-	-	5.7	+470.0	10.0	+96.1
Cost of sales	133.1	137.3	25.0	56.3	87.6	127.0	43.7	+74.8	83.9	+49.0	143.3	+63.6	-	-	83.9	+49.0	-	-
(% of Sales)	40.8	41.2	37.9	38.9	39.0	39.5	47.0	-	45.1	-	47.2	-	-	-	45.1	-	-	-
Gross profit	193.0	207.5	41.2	89.6	142.1	199.9	51.0	+23.8	107.8	+20.3	166.4	+17.1	-	-	107.8	+20.3	-	-
(% of Revenues)	59.2	60.2	62.2	61.4	61.9	61.2	53.9	-	56.2	-	53.7	-	-	-	56.2	-	-	-
SG&A (excl. R&D) expenses	80.1	86.6	19.4	42.2	65.9	95.1	21.6	+11.3	46.1	+9.2	69.8	+5.9	-	-	46.1	+9.2	-	-
(% of Revenues)	24.6	25.1	29.3	28.9	28.7	29.1	22.8	-	24.0	-	22.5	-	-	-	24.0	-	-	-
R&D expenses	54.6	54.2	11.8	24.2	36.3	53.2	11.8	+0.0	24.5	+1.2	37.8	+4.1	-	-	24.5	+1.2	-	-
(% of Revenues)	16.7	15.7	17.8	16.6	15.8	16.3	12.5	-	12.8	-	12.2	-	-	-	12.8	-	-	-
Operating income	58.3	66.7	10.1	23.1	39.8	51.6	17.5	+73.3	37.2	+61.0	58.8	+47.7	-	-	37.2	+61.0	67.0	+29.8
(% of Revenues)	17.9	19.3	15.3	15.8	17.3	15.8	18.5	-	19.4	-	19.0	-	-	-	19.4	-	16.0	-
Non-operating income	6.3	4.3	1.3	2.4	4.3	9.9	5.4	+315.4	6.9	+187.5	7.8	+81.4	-	-	6.9	+187.5	-	-
Non-operating expenses	3.7	3.3	1.1	1.2	1.4	4.2	0.2	-81.8	0.6	-50.0	0.5	-64.3	-	-	0.6	-50.0	-	-
Recurring profit	60.9	67.7	10.2	24.3	42.7	57.3	22.8	+123.5	43.5	+79.0	66.0	+54.6	-	-	43.5	+79.0	74.0	+29.1
(% of Revenues)	18.7	19.6	15.4	16.7	18.6	17.5	24.1	-	22.7	-	21.3	-	-	-	22.7	-	17.6	-
Extraordinary gain	3.6	0.3	0.9	7.2	7.3	7.3	0.3	-66.7	0.3	-95.8	0.3	-95.9	-	-	0.3	-95.8	-	-
Extraordinary loss	1.6	1.6	0.1	0.3	0.4	1.4	0.0	-100.0	0.1	-66.7	0.1	-75.0	-	-	0.1	-66.7	-	-
Income before income taxes etc.	63.0	66.4	11.0	31.2	49.6	63.1	23.1	+110.0	43.7	+40.1	66.3	+33.7	-	-	43.7	+40.1	-	-
(% of Revenues)	19.3	19.3	16.6	21.4	21.6	19.3	24.4	-	22.8	-	21.4	-	-	-	22.8	-	-	-
Net income	38.4	40.1	6.7	18.9	30.1	39.3	13.8	+106.0	26.3	+39.2	40.9	+35.9	-	-	26.3	+39.2	46.0	+17.0
(% of Revenues)	11.8	11.6	10.1	13.0	13.1	12.0	14.6	-	13.7	-	13.2	-	-	-	13.7	-	11.0	-

Note: Other operating revenues (presented as royalties and other operating income through the fiscal year ended December 2008) were previously included in non-operating income or extraordinary gain, but beginning in the fiscal year ended December 31, 2007, they have been included in revenues.

Financial Highlights (QTR)

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009								Forecasts				
	1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	FY2009				
	Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1-6	Change (%)	7-12	Change (%)	
															1st Half(Actual)		2nd Half		
Revenues	326.1	344.8	66.2	79.7	83.8	97.3	94.7	+43.1	97.0	+21.7	118.0	+40.8	-	-	191.7	+31.4	228.3	+26.1	
Sales	326.1	332.9	65.9	79.0	80.0	97.0	92.9	+41.0	93.0	+17.7	117.5	+46.9	-	-	185.9	+28.3	224.1	+26.7	
excl. Tamiflu	288.2	294.3	64.4	78.9	79.9	90.3	72.5	+12.6	88.1	+11.7	87.0	+8.9	-	-	160.6	+12.1	184.6	+8.5	
Tamiflu	38.0	38.7	1.6	0.0	0.1	6.7	20.4	+1,175.0	5.0	-	30.4	+30,300.0	-	-	25.4	+1,487.5	39.5	+480.9	
Ordinary sales	13.6	10.2	1.3	0.0	0.1	5.6	6.0	+361.5	5.0	-	7.6	+7,500.0	-	-	11.0	+685.7	-	-	
Govt. stockpile etc.	24.4	28.5	0.2	-	-	1.1	14.4	+7,100.0	-	-	22.9	-	-	-	14.4	+7,100.0	-	-	
Other operating revenues	-	11.9	0.2	0.8	3.8	0.3	1.8	+800.0	4.0	+400.0	0.5	-86.8	-	-	5.7	+470.0	4.3	+4.9	
Cost of sales	133.1	137.3	25.0	31.3	31.3	39.4	43.7	+74.8	40.1	+28.1	59.4	+89.8	-	-	83.9	+49.0	-	-	
(% of Sales)	40.8	41.2	37.9	39.6	39.1	40.6	47.0	-	43.1	-	50.6	-	-	-	45.1	-	-	-	
Gross profit	193.0	207.5	41.2	48.4	52.5	57.8	51.0	+23.8	56.9	+17.6	58.6	+11.6	-	-	107.8	+20.3	-	-	
(% of Revenues)	59.2	60.2	62.2	60.7	62.6	59.4	53.9	-	58.7	-	49.7	-	-	-	56.2	-	-	-	
SG&A (excl. R&D) expenses	80.1	86.6	19.4	22.8	23.7	29.2	21.6	+11.3	24.5	+7.5	23.7	+0.0	-	-	46.1	+9.2	-	-	
(% of Revenues)	24.6	25.1	29.3	28.6	28.3	30.0	22.8	-	25.3	-	20.1	-	-	-	24.0	-	-	-	
R&D expenses	54.6	54.2	11.8	12.5	12.1	16.9	11.8	+0.0	12.7	+1.6	13.3	+9.9	-	-	24.5	+1.2	-	-	
(% of Revenues)	16.7	15.7	17.8	15.7	14.4	17.4	12.5	-	13.1	-	11.3	-	-	-	12.8	-	-	-	
Operating income	58.3	66.7	10.1	13.1	16.7	11.7	17.5	+73.3	19.6	+49.6	21.6	+29.3	-	-	37.2	+61.0	29.8	+4.9	
(% of Revenues)	17.9	19.3	15.3	16.4	19.9	12.0	18.5	-	20.2	-	18.3	-	-	-	19.4	-	13.1	-	
Non-operating income	6.3	4.3	1.3	1.2	1.9	5.6	5.4	+315.4	1.5	+25.0	1.2	-36.8	-	-	6.9	+187.5	-	-	
Non-operating expenses	3.7	3.3	1.1	0.1	0.2	2.8	0.2	-81.8	0.5	+400.0	0.2	+0.0	-	-	0.6	-50.0	-	-	
Recurring profit	60.9	67.7	10.2	14.1	18.4	14.6	22.8	+123.5	20.7	+46.8	22.6	+22.8	-	-	43.5	+79.0	30.6	-7.0	
(% of Revenues)	18.7	19.6	15.4	17.7	22.0	15.0	24.1	-	21.3	-	19.2	-	-	-	22.7	-	13.4	-	
Extraordinary gain	3.6	0.3	0.9	6.3	0.0	0.0	0.3	-66.7	-	-100.0	0.0	-	-	-	0.3	-95.8	-	-	
Extraordinary loss	1.6	1.6	0.1	0.2	0.0	1.1	0.0	-100.0	0.0	-100.0	0.0	-	-	-	0.1	-66.7	-	-	
Income before income taxes etc.	63.0	66.4	11.0	20.2	18.4	13.5	23.1	+110.0	20.6	+2.0	22.6	+22.8	-	-	43.7	+40.1	-	-	
(% of Revenues)	19.3	19.3	16.6	25.3	22.0	13.9	24.4	-	21.2	-	19.2	-	-	-	22.8	-	-	-	
Net income	38.4	40.1	6.7	12.2	11.3	9.1	13.8	+106.0	12.5	+2.5	14.6	+29.2	-	-	26.3	+39.2	19.7	-3.4	
(% of Revenues)	11.8	11.6	10.1	15.3	13.5	9.4	14.6	-	12.9	-	12.4	-	-	-	13.7	-	8.6	-	

Statements of Revenues (YTD)

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009							Forecasts						
			FY2008			FY2009							FY2009							
			1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
			Full-year	Full-year	YTD	YTD	YTD	YTD	YTD	(%)	YTD	(%)	YTD	(%)	YTD	(%)	Half-year(Actual)	(%)	Full-year	(%)
Sales	326.1	332.9	65.9	144.9	224.9	321.8	92.9	+41.0	185.9	+28.3	303.4	+34.9	-	-	185.9	+28.3	410.0	+27.4		
Excl. Tamiflu	288.2	294.3	64.4	143.3	223.2	313.4	72.5	+12.6	160.6	+12.1	247.6	+10.9	-	-	160.6	+12.1	345.2	+10.1		
Domestic	259.8	263.1	56.6	127.7	198.3	279.9	66.2	+17.0	146.3	+14.6	223.9	+12.9	-	-	146.3	+14.6	315.2	+12.6		
Oncology field	67.8	74.0	18.9	44.0	70.8	102.3	25.7	+36.0	57.8	+31.4	88.9	+25.6	-	-	57.8	+31.4	124.2	+21.4		
Herceptin	14.5	16.1	4.1	9.8	16.2	23.7	6.6	+61.0	14.7	+50.0	22.0	+35.8	-	-	14.7	+50.0	30.0	+26.6		
Rituxan	18.0	18.6	4.2	9.5	14.6	20.5	4.3	+2.4	9.7	+2.1	15.1	+3.4	-	-	9.7	+2.1	21.2	+3.4		
Avastin *1	-	3.5	2.7	7.1	12.8	20.1	6.7	+148.1	15.4	+116.9	24.3	+89.8	-	-	15.4	+116.9	33.6	+67.2		
Neutrogen	12.0	12.6	2.4	5.4	8.5	12.0	2.2	-8.3	5.2	-3.7	8.2	-3.5	-	-	5.2	-3.7	12.0	+0.0		
Kytril	12.9	13.6	2.5	5.4	8.1	10.9	2.1	-16.0	4.5	-16.7	6.6	-18.5	-	-	4.5	-16.7	9.3	-14.7		
Xeloda	2.5	2.7	0.8	2.0	3.3	4.8	1.3	+62.5	2.8	+40.0	4.4	+33.3	-	-	2.8	+40.0	6.5	+35.4		
Tarceva *1	-	0.2	0.8	2.0	3.2	4.5	1.2	+50.0	2.7	+35.0	4.1	+28.1	-	-	2.7	+35.0	5.6	+24.4		
Femara *1	0.3	1.0	0.3	0.7	1.2	1.7	0.5	+66.7	1.1	+57.1	1.7	+41.7	-	-	1.1	+57.1	2.6	+52.9		
Other products	7.6	5.6	1.0	2.1	3.1	4.1	0.8	-20.0	1.7	-19.0	2.5	-19.4	-	-	1.7	-19.0	3.4	-17.1		
Renal diseases field	76.8	69.6	13.7	29.5	44.6	61.3	13.0	-5.1	28.8	-2.4	44.4	-0.4	-	-	28.8	-2.4	61.9	+1.0		
Epogin	63.4	54.8	10.2	21.7	32.8	44.9	9.4	-7.8	20.8	-4.1	32.3	-1.5	-	-	20.8	-4.1	45.2	+0.7		
Oxarol	7.6	8.7	2.1	4.7	7.3	10.0	2.2	+4.8	4.9	+4.3	7.7	+5.5	-	-	4.9	+4.3	10.6	+6.0		
Renagel	5.0	5.6	1.2	2.7	4.1	5.7	1.3	+8.3	2.7	+0.0	4.0	-2.4	-	-	2.7	+0.0	5.3	-7.0		
Other products	0.7	0.5	0.2	0.4	0.4	0.7	0.2	+0.0	0.4	+0.0	0.5	+25.0	-	-	0.4	+0.0	0.7	+0.0		
Bone and joint diseases field	42.2	46.6	9.8	22.7	35.2	50.0	12.2	+24.5	26.9	+18.5	41.2	+17.0	-	-	26.9	+18.5	58.9	+17.8		
Evista	13.4	16.0	3.1	7.5	11.7	16.5	3.8	+22.6	8.4	+12.0	12.8	+9.4	-	-	8.4	+12.0	18.1	+9.7		
Alfarol	14.6	14.3	3.0	6.7	10.0	13.7	3.0	+0.0	6.5	-3.0	9.9	-1.0	-	-	6.5	-3.0	13.6	-0.7		
Suvenyl	9.1	11.0	2.5	5.6	8.7	12.0	2.8	+12.0	6.5	+16.1	10.0	+14.9	-	-	6.5	+16.1	13.7	+14.2		
Actemra	0.4	0.5	0.1	0.7	1.8	3.4	1.5	+1,400.0	3.5	+400.0	5.7	+216.7	-	-	3.5	+400.0	9.6	+182.4		
Other products	4.6	4.8	1.1	2.2	3.1	4.5	1.1	+0.0	2.1	-4.5	2.8	-9.7	-	-	2.1	-4.5	3.9	-13.3		
Transplant, Immunology & Infectious diseases field	14.5	17.7	4.8	10.7	16.8	24.0	5.9	+22.9	12.8	+19.6	19.3	+14.9	-	-	12.8	+19.6	28.3	+17.9		
Pegasys	5.8	6.3	1.9	4.1	6.7	9.7	2.5	+31.6	5.5	+34.1	8.2	+22.4	-	-	5.5	+34.1	12.3	+26.8		
Copegus *1	-	2.0	0.8	1.8	2.9	4.2	1.1	+37.5	2.4	+33.3	3.6	+24.1	-	-	2.4	+33.3	5.6	+33.3		
Rocephin	5.5	5.7	1.3	2.8	4.2	5.9	1.3	+0.0	2.7	-3.6	4.1	-2.4	-	-	2.7	-3.6	5.8	-1.7		
CellCept	3.0	3.5	0.8	1.9	2.8	4.0	0.9	+12.5	2.1	+10.5	3.2	+14.3	-	-	2.1	+10.5	4.5	+12.5		
Other products	0.3	0.3	0.1	0.1	0.2	0.3	0.1	+0.0	0.1	+0.0	0.2	+0.0	-	-	0.1	+0.0	0.2	-33.3		
Others field	58.4	55.1	9.5	20.8	30.8	42.3	9.4	-1.1	20.0	-3.8	30.1	-2.3	-	-	20.0	-3.8	41.7	-1.4		
Sigmart	15.4	15.2	3.3	7.3	10.8	15.0	3.3	+0.0	7.1	-2.7	10.6	-1.9	-	-	7.1	-2.7	14.9	-0.7		
SA products *2	12.9	11.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Other products	30.1	28.8	6.1	13.5	20.0	27.3	6.2	+1.6	13.0	-3.7	19.4	-3.0	-	-	13.0	-3.7	26.8	-1.8		
Overseas	28.4	31.2	7.8	15.6	24.9	33.5	6.3	-19.2	14.2	-9.0	23.7	-4.8	-	-	14.2	-9.0	30.0	-10.4		
Neutrogen	24.2	26.6	6.7	13.3	20.1	25.9	4.8	-28.4	10.2	-23.3	15.8	-21.4	-	-	10.2	-23.3	19.4	-25.1		
Sigmart	2.6	2.8	0.6	1.2	1.7	2.0	0.6	+0.0	1.3	+8.3	1.5	-11.8	-	-	1.3	+8.3	2.0	+0.0		
Actemra	-	-	-	0.2	1.7	3.8	0.4	-	1.8	+800.0	5.1	+200.0	-	-	1.8	+800.0	7.1	+86.8		
Other products	1.6	1.9	0.5	0.9	1.4	1.7	0.5	+0.0	1.0	+11.1	1.2	-14.3	-	-	1.0	+11.1	1.5	-11.8		
Tamiflu	38.0	38.7	1.6	1.6	1.7	8.4	20.4	+1,175.0	25.4	+1,487.5	55.8	+3,182.4	-	-	25.4	+1,487.5	64.9	+672.6		
Ordinary sales	13.6	10.2	1.3	1.4	1.5	7.1	6.0	+361.5	11.0	+685.7	18.5	+1,133.3	-	-	11.0	+685.7	-	-		
Govt. stockpile etc.	24.4	28.5	0.2	0.2	0.2	1.3	14.4	+7,100.0	14.4	+7,100.0	37.3	+18,550.0	-	-	14.4	+7,100.0	-	-		
Other operating revenues	-	11.9	0.2	1.0	4.8	5.1	1.8	+800.0	5.7	+470.0	6.3	+31.3	-	-	5.7	+470.0	10.0	+96.1		
Revenues (total)	326.1	344.8	66.2	145.9	229.7	326.9	94.7	+43.1	191.7	+31.4	309.7	+34.8	-	-	191.7	+31.4	420.0	+28.5		
Domestic	297.7	308.4	58.3	130.2	204.6	293.1	86.7	+48.7	175.5	+34.8	283.7	+38.7	-	-	175.5	+34.8	387.2	+32.1		
Overseas	28.4	36.4	7.8	15.7	25.0	33.8	8.0	+2.6	16.2	+3.2	26.1	+4.4	-	-	16.2	+3.2	32.8	-3.0		

Notes: 1. The products marketed in 2006 and subsequent years are as follows: Avastin (launched in June 2007), Tarceva (December 2007), Femara (May 2006), Copegus (March 2007).
2. Sales of the products for which the marketing collaboration in Japan with sanofi-aventis K.K. ended on December 31, 2007, are included in the "Others field (SA products)."

Statements of Revenues (QTR)

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009						Forecasts							
			1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	FY2009			
																	Full-year	Full-year	QTR	QTR
			1st Half(Actual)	Change (%)	2nd Half	Change (%)														
Sales	326.1	332.9	65.9	79.0	80.0	97.0	92.9	+41.0	93.0	+17.7	117.5	+46.9	--	--	185.9	+28.3	224.1	+26.7		
Excl. Tamiflu	288.2	294.3	64.4	78.9	79.9	90.3	72.5	+12.6	88.1	+11.7	87.0	+8.9	--	--	160.6	+12.1	184.6	+8.5		
Domestic	259.8	263.1	56.6	71.1	70.6	81.7	66.2	+17.0	80.1	+12.7	77.6	+9.9	--	--	146.3	+14.6	168.8	+10.9		
Oncology field	67.8	74.0	18.9	25.2	26.8	31.4	25.7	+36.0	32.1	+27.4	31.1	+16.0	--	--	57.8	+31.4	66.5	+14.3		
Herceptin	14.5	16.1	4.1	5.7	6.4	7.5	6.6	+61.0	8.1	+42.1	7.3	+14.1	--	--	14.7	+50.0	15.3	+9.3		
Rituxan	18.0	18.6	4.2	5.3	5.1	5.9	4.3	+2.4	5.5	+3.8	5.4	+5.9	--	--	9.7	+2.1	11.4	+3.6		
Avastin	--	3.5	2.7	4.4	5.6	7.3	6.7	+148.1	8.6	+95.5	8.9	+58.9	--	--	15.4	+116.9	18.3	+40.8		
Neutrogin	12.0	12.6	2.4	3.0	3.1	3.5	2.2	-8.3	3.0	+0.0	3.0	-3.2	--	--	5.2	-3.7	6.8	+4.6		
Kytril	12.9	13.6	2.5	2.8	2.7	2.8	2.1	-16.0	2.4	-14.3	2.1	-22.2	--	--	4.5	-16.7	4.9	-10.9		
Xeloda	2.5	2.7	0.8	1.2	1.3	1.5	1.3	+62.5	1.5	+25.0	1.6	+23.1	--	--	2.8	+40.0	3.7	+37.0		
Tarceva	--	0.2	0.8	1.2	1.2	1.4	1.2	+50.0	1.5	+25.0	1.4	+16.7	--	--	2.7	+35.0	2.9	+16.0		
Femara	0.3	1.0	0.3	0.4	0.4	0.5	0.5	+66.7	0.6	+50.0	0.6	+50.0	--	--	1.1	+57.1	1.6	+60.0		
Other products	7.6	5.6	1.0	1.2	1.0	1.1	0.8	-20.0	0.9	-25.0	0.8	-20.0	--	--	1.7	-19.0	1.7	-15.0		
Renal diseases field	76.8	69.6	13.7	15.8	15.1	16.7	13.0	-5.1	15.8	+0.0	15.6	+3.3	--	--	28.8	-2.4	33.1	+4.1		
Epogin	63.4	54.8	10.2	11.5	11.1	12.1	9.4	-7.8	11.5	+0.0	11.4	+2.7	--	--	20.8	-4.1	24.4	+5.2		
Oxarol	7.6	8.7	2.1	2.6	2.5	2.8	2.2	+4.8	2.8	+7.7	2.7	+8.0	--	--	4.9	+4.3	5.7	+7.5		
Renagel	5.0	5.6	1.2	1.5	1.4	1.6	1.3	+8.3	1.4	-6.7	1.3	-7.1	--	--	2.7	+0.0	2.7	-10.0		
Other products	0.7	0.5	0.2	0.2	0.1	0.3	0.2	+0.0	0.1	-50.0	0.2	+100.0	--	--	0.4	+0.0	0.4	+0.0		
Bone and joint diseases field	42.2	46.6	9.8	12.9	12.5	14.8	12.2	+24.5	14.8	+14.7	14.3	+14.4	--	--	26.9	+18.5	32.0	+17.2		
Evista	13.4	16.0	3.1	4.4	4.1	4.8	3.8	+22.6	4.6	+4.5	4.4	+7.3	--	--	8.4	+12.0	9.8	+10.1		
Alfarol	14.6	14.3	3.0	3.7	3.3	3.7	3.0	+0.0	3.5	-5.4	3.3	+0.0	--	--	6.5	-3.0	7.1	+1.4		
Suvenyl	9.1	11.0	2.5	3.2	3.0	3.3	2.8	+12.0	3.7	+15.6	3.5	+16.7	--	--	6.5	+16.1	7.2	+12.5		
Actemra	0.4	0.5	0.1	0.6	1.1	1.6	1.5	+1,400.0	2.0	+233.3	2.2	+100.0	--	--	3.5	+400.0	6.1	+125.9		
Other products	4.6	4.8	1.1	1.1	0.9	1.4	1.1	+0.0	1.0	-9.1	0.8	-11.1	--	--	2.1	-4.5	1.9	-13.6		
Transplant, Immunology & Infectious diseases field	14.5	17.7	4.8	5.9	6.1	7.2	5.9	+22.9	6.9	+16.9	6.5	+6.6	--	--	12.8	+19.6	15.5	+16.5		
Pegasys	5.8	6.3	1.9	2.3	2.6	3.0	2.5	+31.6	2.9	+26.1	2.8	+7.7	--	--	5.5	+34.1	6.8	+21.4		
Copegus	--	2.0	0.8	1.0	1.1	1.3	1.1	+37.5	1.3	+30.0	1.2	+9.1	--	--	2.4	+33.3	3.2	+33.3		
Rocephin	5.5	5.7	1.3	1.5	1.4	1.7	1.3	+0.0	1.5	+0.0	1.4	+0.0	--	--	2.7	-3.6	3.0	-3.2		
CellCept	3.0	3.5	0.8	1.1	1.0	1.1	0.9	+12.5	1.1	+0.0	1.1	+10.0	--	--	2.1	+10.5	2.4	+14.3		
Other products	0.3	0.3	0.1	0.1	0.1	0.1	0.1	+0.0	0.1	+0.0	0.1	+0.0	--	--	0.1	+0.0	0.1	+0.0		
Others field	58.4	55.1	9.5	11.3	10.0	11.5	9.4	-1.1	10.6	-6.2	10.0	+0.0	--	--	20.0	-3.8	21.7	+0.9		
Sigmart	15.4	15.2	3.3	4.0	3.5	4.1	3.3	+0.0	3.8	-5.0	3.6	+2.9	--	--	7.1	-2.7	7.9	+3.9		
SA products	12.9	11.2	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--		
Other products	30.1	28.8	6.1	7.4	6.5	7.3	6.2	+1.6	6.8	-8.1	6.5	+0.0	--	--	13.0	-3.7	13.9	+0.0		
Overseas	28.4	31.2	7.8	7.8	9.3	8.6	6.3	-19.2	7.9	+1.3	9.5	+2.2	--	--	14.2	-9.0	15.8	-11.7		
Neutrogin	24.2	26.6	6.7	6.6	6.8	5.8	4.8	-28.4	5.4	-18.2	5.6	-17.6	--	--	10.2	-23.3	9.2	-27.0		
Sigmart	2.6	2.8	0.6	0.6	0.5	0.3	0.6	+0.0	0.6	+0.0	0.3	-40.0	--	--	1.3	+8.3	0.7	-22.2		
Actemra	--	--	--	0.2	1.5	2.2	0.4	--	1.4	+600.0	3.3	+120.0	--	--	1.8	+800.0	5.3	+47.2		
Other products	1.6	1.9	0.5	0.5	0.5	0.3	0.5	+0.0	0.5	+0.0	0.2	-60.0	--	--	1.0	+11.1	0.5	-37.5		
Tamiflu	38.0	38.7	1.6	0.0	0.1	6.7	20.4	+1,175.0	5.0	--	30.4	+30,300.0	--	--	25.4	+1,487.5	39.5	+480.9		
Ordinary sales	13.6	10.2	1.3	0.0	0.1	5.6	6.0	+361.5	5.0	--	7.6	+7,500.0	--	--	11.0	+685.7	--	--		
Govt. stockpile etc.	24.4	28.5	0.2	--	--	1.1	14.4	+7,100.0	--	--	22.9	--	--	--	14.4	+7,100.0	--	--		
Other operating revenues	--	11.9	0.2	0.8	3.8	0.3	1.8	+800.0	4.0	+400.0	0.5	-86.8	--	--	5.7	+470.0	4.3	+4.9		
Revenues (total)	326.1	344.8	66.2	79.7	83.8	97.3	94.7	+43.1	97.0	+21.7	118.0	+40.8	--	--	191.7	+31.4	228.3	+26.1		
Domestic	297.7	308.4	58.3	71.9	74.4	88.5	86.7	+48.7	88.8	+23.5	108.1	+45.3	--	--	175.5	+34.8	211.7	+30.0		
Overseas	28.4	36.4	7.8	7.8	9.4	8.8	8.0	+2.6	8.2	+5.1	9.9	+5.3	--	--	16.2	+3.2	16.6	-8.3		

Balance Sheets

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009					
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	vs. Sep. 30, 2008	vs. Dec. 31, 2008	As of Dec. 31
Cash and deposits	68.3	73.2	70.0	72.6	65.4	70.8	77.6	90.8	77.6	+12.2	+6.8	-
Trade notes and accounts receivable	105.9	107.0	84.6	93.5	93.3	108.5	111.3	102.7	121.8	+28.5	+13.3	-
Marketable securities	81.9	65.5	61.9	65.9	66.3	54.7	46.0	54.5	55.6	-10.7	+0.9	-
Inventories	61.5	55.2	58.4	63.9	72.7	78.7	78.7	94.0	90.4	+17.7	+11.7	-
Other current assets	20.0	28.9	31.4	27.4	29.9	31.7	34.3	30.9	32.3	+2.4	+0.6	-
Total Current assets	337.7	329.8	306.3	323.3	327.6	344.4	347.9	372.9	377.7	+50.1	+33.3	-
Tangible fixed assets	85.2	92.5	98.9	101.2	99.3	98.3	97.1	96.2	93.7	-5.6	-4.6	-
Intangible fixed assets	5.1	3.7	3.3	4.0	3.5	3.1	3.2	3.0	2.7	-0.8	-0.4	-
Investments and other assets	34.2	32.9	35.5	33.5	31.5	32.7	30.6	29.6	31.2	-0.3	-1.5	-
thereof Investment securities	15.1	16.8	20.5	19.1	16.0	14.4	11.8	10.6	9.8	-6.2	-4.6	-
Total Fixed Assets	124.5	129.1	137.7	138.7	134.2	134.2	130.9	128.8	127.6	-6.6	-6.6	-
Total Assets	462.1	458.9	444.0	462.0	461.9	478.5	478.7	501.7	505.3	+43.4	+26.8	-
Notes and accounts payable	28.1	17.3	18.8	22.2	24.6	28.8	34.0	37.8	34.3	+9.7	+5.5	-
Short-term borrowings and bonds	-	0.3	0.3	0.3	-	-	-	-	-	-	-	-
Other current liabilities	37.1	52.1	39.9	39.8	39.7	49.8	41.4	44.7	49.0	+9.3	-0.8	-
Total current liabilities	65.3	69.8	59.0	62.4	64.3	78.5	75.4	82.5	83.3	+19.0	+4.8	-
Long-term debt and bonds	0.5	-	-	-	-	-	-	-	-	-	-	-
Other fixed liabilities	4.8	3.3	3.1	3.0	3.1	2.9	3.0	3.3	3.6	+0.5	+0.7	-
Total fixed liabilities	5.3	3.3	3.1	3.0	3.1	2.9	3.0	3.3	3.6	+0.5	+0.7	-
Total liabilities	70.5	73.1	62.2	65.4	67.4	81.5	78.4	85.8	86.9	+19.5	+5.4	-
Common stock	72.9	72.9	72.9	73.0	73.0	73.0	73.0	73.0	73.0	+0.0	+0.0	-
Additional paid-in capital	92.7	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	+0.0	+0.0	-
Retained earnings	226.2	248.1	246.6	258.8	261.9	271.0	274.4	286.9	292.3	+30.4	+21.3	-
Treasury stock, at cost	-7.6	-35.1	-35.1	-35.1	-35.2	-35.2	-35.2	-35.2	-36.3	-1.1	-1.1	-
Net unrealized gain on securities	3.2	2.8	2.9	3.2	1.7	1.4	0.9	2.0	1.7	+0.0	+0.3	-
Foreign currency translation adjustments	2.1	1.9	-0.3	1.3	-1.6	-7.9	-7.3	-5.8	-6.9	-5.3	+1.0	-
New share warrants	-	0.1	0.2	0.2	0.3	0.3	0.4	0.4	0.5	+0.2	+0.2	-
Minority interests	2.0	2.2	1.8	2.3	1.6	1.7	1.3	1.8	1.4	-0.2	-0.3	-
Total net assets	391.6	385.8	381.8	396.6	394.5	397.1	400.4	416.0	418.4	+23.9	+21.3	-
Total liabilities and net assets	462.1	458.9	444.0	462.0	461.9	478.5	478.7	501.7	505.3	+43.4	+26.8	-

Cash Flows

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009			
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
Net cash provided by (used in) operating activities	40.5	60.4	9.8	23.5	32.6	39.3	13.0	33.7	36.9	-
Net cash provided by (used in) investing activities	-29.4	-7.5	-2.2	-14.7	-19.1	-14.1	-3.9	-13.3	-21.6	-
Net cash provided by (used in) financing activities	-18.8	-47.2	-8.8	-8.8	-18.4	-18.4	-11.0	-11.0	-22.3	-
Effect of exchange rate changes on cash and cash equivalents	1.6	-0.3	-2.2	-0.7	-3.4	-9.9	-0.6	0.6	1.0	-
Net increase (decrease) in cash and cash equivalents	-6.0	5.4	-3.3	-0.7	-8.3	-3.1	-2.5	9.9	-6.1	-
Cash and cash equivalents at beginning of period	74.4	68.3	73.7	73.7	73.7	73.7	70.7	70.7	70.7	-
Cash and cash equivalents at end of period	68.3	73.7	70.4	73.1	65.4	70.7	68.1	80.6	64.6	-

Performance Indicators

	FY2006	FY2007	FY2008				FY2009				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2009
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Net income per share (Basic)	69.35yen	73.23yen	12.30yen	34.64yen	55.32yen	72.07yen	25.27yen	48.29yen	75.07yen	-	84.53yen
Net income per share (Fully diluted)	69.26yen	73.16yen	12.29yen	34.62yen	55.32yen	72.04yen	25.27yen	48.28yen	75.06yen	-	-
Return on equity (ROE)*	10.1%	10.4%	1.8%	4.9%	7.8%	10.1%	3.5%	6.5%	10.1%	-	-
Return on assets (ROA)*	13.3%	14.7%	2.3%	5.3%	9.3%	12.2%	4.8%	8.9%	13.4%	-	-
Net assets per share	703.08yen	703.80yen	697.17yen	723.10yen	720.66yen	725.18yen	731.74yen	759.41yen	765.47yen	-	-
Equity ratio	84.3%	83.5%	85.6%	85.3%	85.0%	82.6%	83.3%	82.5%	82.4%	-	-
Dividends per share (Annual)	30yen	30yen				34yen				-	34yen
Dividends per share (Interim)	12yen	15yen				15yen				17yen	17yen
Payout ratio	43.3%	41.0%				47.2%				-	40.2%

Note: Quarterly (year-to-date) ROE and ROA are not annualized.

Number of Employees

	FY2006	FY2007	FY2008				FY2009				Forecast
	As of Dec. 31	As of Dec. 31	As of Jun. 30	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	FY2009	
	As of Dec. 31	As of Dec. 31	As of Jun. 30	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31	
Number of employees	5,905	6,257	6,408	6,383	6,347	6,474	6,481	-	6,500		

Note: Number of employees doesn't include staff seconded to companies outside the Group.

Capital Expenditures

(Billions of Yen)

	FY2006	FY2007	FY2008				FY2009				Forecast
	1-12	1-12	1-6	1-12	1-12	1-3	1-6	1-9	1-12	FY2009	
	Full-year	Full-year	YTD	Full-year	Full-year	YTD	YTD	YTD	Full-year	Full-year	
Capital expenditures	16.3	19.6	17.9	26.6	2.8	6.6	9.1	-	16.0		
Depreciation	12.3	13.3	8.6	19.4	4.2	8.9	14.1	-	20.7		

Development pipeline (as of October 27, 2009)

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
RG340	Colorectal cancer #	Launched Sep. 09	capecitabine Xeloda	Roche Xeloda	Antimetabolite, 5-FU derivative
	Gastric cancer #	Phase III	Oral		
RG435	Non-small cell lung cancer #	Filed Nov. 08	bevacizumab Avastin	Roche /Genentech Avastin	Humanized anti-VEGF(Vascular Endothelial Growth Factor) monoclonal antibody
	Breast cancer #	Filed Oct. 09	Injection		
	Colon cancer (adjuvant) #	Phase III Multinational study			
	Gastric cancer #	Phase III Multinational study			
	Breast cancer (adjuvant) #	Phase III Multinational study			
	Glioblastoma #	Phase III Multinational study			
	Glioblastoma (relapsed) #	Phase II			
RG1415	Pancreatic cancer #	Filed Sep. 09	erlotinib Tarceva Oral	OSI/Genentech/ Roche Tarceva	EGFR tyrosine kinase inhibitor
RG597	Gastric cancer #	Phase III Multinational study	trastuzumab Herceptin Injection	Roche /Genentech Herceptin	Humanized anti-HER2 monoclonal antibody
RG1273	Breast cancer	Phase III Multinational study	pertuzumab Injection	Roche /Genentech	Humanized HER dimerization inhibitory monoclonal antibody
EPOCH	Chemotherapy-induced anemia #	Phase III	epoetin beta Epogin Injection	In-house	Recombinant human erythropoietin
TP300	Gastric cancer, etc	Phase II Overseas	Injection	In-house	Topoisomerase I inhibitor

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
MRA	Pancreatic cancer #	Phase I/II	tocilizumab Actemra Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody
CIF (RG7167)	Solid tumors	Phase I Overseas	Oral	In-house (Roche)	MEK inhibitor
GC33	Liver cancer	Phase I Overseas	Injection	In-house	Humanized anti-Glypican-3 monoclonal antibody
RG7159 (GA101)	Non-Hodgkin's lymphoma	Phase I	Injection	Roche/GlycArt	Humanized anti-CD20 monoclonal antibody
CKI27 (RG7304)	Solid tumors	Phase I Overseas	Oral	In-house (Roche)	-
RG1507	Solid tumors	Phase I	Injection	Roche	Human anti-IGF-1R monoclonal antibody
RG3502	Breast cancer	Phase I	Injection	Roche /Genentech	HER2 antibody-drug conjugate
Bone and Joint diseases					
MRA	Rheumatoid arthritis #	Filed Nov. 07 Overseas(US)	tocilizumab Actemra(US) / RoActemra (EU) Injection	In-house (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
	Systemic onset juvenile idiopathic arthritis (sJIA) #	Phase III Overseas			
	Rheumatoid arthritis (new formulation: subcutaneous injection)	Phase I / II	tocilizumab Actemra Injection		
ED-71	Osteoporosis	Filed Oct. 09	eldecacitol Oral	In-house (Taisho Pharmaceutical)	Activated Vitamin D ₃ derivative

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG1594	Rheumatoid arthritis	Phase III Multinational study	ocrelizumab Injection	Roche /Genentech	Humanized anti-CD20 monoclonal antibody
RG484	Osteoporosis	Phase II / III	ibandronate sodium hydrate Injection	Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical)	Bisphosphonate
		Phase II	ibandronate sodium hydrate Oral		
Renal diseases					
RG744	Renal anemia	Filed Jul. 09	Injection	Roche Mircera	Continuous erythropoietin receptor activator
Transplant, Immunology and Infectious diseases					
RG964	Compensated liver cirrhosis caused by hepatitis C virus	Phase II / III	ribavirin Copegus Oral	Roche Copegus	Anti-viral agent in combination with Pegasys
RG442	# Chronic hepatitis B		Phase II / III	peginterferon alfa-2a Pegasys Injection	Roche Pegasys
NA808	Chronic hepatitis C	Phase I Japan	Injection	In-house	Serine palmitoyltransferase inhibitor
		Phase I Overseas			
NTZ	Chronic hepatitis C	Phase I	nitazoxanide Oral	Romark Laboratories	Thiazolide compound
Other diseases					
EPOCH	Predeposit of autologous blood transfusion #	Filed Mar. 02	epoetin beta Epogin Injection	In-house	Recombinant human erythropoietin
RG1678	Schizophrenia	Phase II Multinational study	Oral	Roche	GLYT1 inhibitor
CSG452 (RG7201)	Type II diabetes	Phase II Multinational study	Oral	In-house (Roche)	SGLT2 inhibitor

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG1583 (ITM-077)	Type II diabetes	Phase II	tasoglutide Injection	Roche / Ipsen (Teijin)	GLP-1 analogue
RG1450	Alzheimer's disease	Phase I	gantenerumab Injection	Roche / Morphosys	Human anti-amyloid-beta monoclonal antibody

Changes from the last announcement on July 23, 2009

Oncology

-RG340 Filed → Launched (colorectal cancer)
 -RG435 Phase II → Filed (breast cancer)
 Phase II (glioblastoma [relapsed])
 -RG1415 Phase II → Filed (pancreatic cancer)
 -MRA Phase I/II (pancreatic cancer)
 -TP300 Phase I → Phase II (gastric cancer, etc)
 -RG3502 Phase I (breast cancer)

Bone and Joint diseases

-ED-71 Phase III → Filed (osteoporosis)

Transplant, Immunology and Infectious diseases

-NTZ Phase I (chronic hepatitis C)

Others

-RG1450 Phase I (Alzheimer's disease)

R&D Activities (Jul. 1, 2009 – Oct. 27, 2009)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- In July, we participated in a multinational Phase III trial (expected indication: breast cancer) conducted by Roche for RG1203, a humanized HER dimerization inhibitory monoclonal antibody.
- In August, we participated in a multinational Phase III trial (expected indication: glioblastoma) conducted by Roche and started a domestic Phase II trial (expected indication: glioblastoma [relapsed]) for a humanized anti-VEGF monoclonal antibody RG435 (product name: Avastin). Also, we filed an application for RG435 (expected indication: breast cancer) in October.
- In September, we obtained approval for an additional indication of RG340 (product name: Xeloda), a 5-FU derivative, for colorectal cancer, as a combination therapy with oxaliplatin.
- In September, we filed an application for an EGFR tyrosine kinase inhibitor, RG1415 (product name: Tarceva, expected indication: pancreatic cancer).
- In September, we started a Phase I/II trial (expected indication: pancreatic cancer) for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra).
- In October, we started a Phase I trial (expected indication: breast cancer) for a HER2 antibody-drug conjugate, RG3502.

Bone and Joint Diseases

- In October, we filed an application for an activated Vitamin D₃ derivative, ED-71 (expected indication: osteoporosis).

Renal Diseases

- In July, we filed an application for a continuous erythropoietin receptor activator, RG744 (expected indication: renal anemia).

Transplant, Immunology and Infectious Diseases

- In August, we started a Phase I trial (expected indication: chronic hepatitis C) for a thiazolide compound, NTZ.

-

Other Diseases

- In July, we started a Phase II trial (expected indication: type II diabetes) for a GLP-1 analogue, RG1583 (ITM-077).
- In October, we started a Phase I trial (expected indication: Alzheimer's disease) for a human anti-amyloid-beta monoclonal antibody, RG1450.

At present, we are awaiting the approval of applications (new molecular entities or additions of indications) filed for 6 development themes, including RG435 (expected indication: non-small cell lung cancer).

Also, as for development activities overseas, the Company saw progress as described below.

- In October, we started a Phase II trial (expected indication: gastric cancer, etc) for a topoisomerase I inhibitor, TP300.

We deleted the following projects from our development pipeline with due consideration for priorities: a humanized anti-human IL-6 receptor monoclonal antibody MRA (expected indication: multiple myeloma, Crohn's disease, Castleman's disease [overseas], Systemic lupus erythematosus (SLE)), a motilin agonist GM-611 (expected indication: diabetic gastroparesis, irritable bowel syndrome (IBS)), a DPP-IV inhibitor RG1579 (expected indication: type II diabetes).

Major clinical trials in oncology field currently running in Japan

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG435 (bevacizumab) Avastin	Non-small cell lung	carboplatin + paclitaxel ± RG435	Filed (Nov. 08)	-
	Breast	paclitaxel + RG435	Filed (Oct. 09)	-
	Breast (adjuvant)	standard chemotherapy ± RG435	BEATRICE study Phase III Multinational study	2012 2014
	Glioblastoma	temozolomide ± RG435	Phase III Multinational study	2012 2014
	Glioblastoma [relapsed]	RG435	Phase II	2012 2014
RG435 (bevacizumab) Avastin	Colon (adjuvant)	FOLFOX4 ± RG435 XELOX + RG435	AVANT study : Phase III Multinational study	2011
RG340 (capecitabine) Xeloda	Gastric	RG340(5FU) + CDDP ± RG435	AVAGAST study : Phase III Multinational study	2011
RG1415 (erlotinib) Tarceva	Pancreatic	gemcitabine + RG1415	Filed (Sep. 09)	-
RG597 (trastuzumab) Herceptin RG340 (capecitabine) Xeloda	Gastric	RG40/5FU + CDDP ± RG597	ToGA study : Phase III Multinational study	2010
RG1273 (pertuzumab)	Breast	RG597 + docetaxel ± RG1273	CLEOPATRA study Phase III Multinational study	2012 2014